

1 **Influence of blood pressure on pneumonia risk:**  
2 **Epidemiological association and Mendelian randomisation in the UK Biobank**  
3  
4

5 Seyedeh M. Zekavat BS (1-4; ORCID: 0000-0003-4026-8944), Michael Honigberg MD MPP (3-  
6 6), James Pirruccello MD (3-6), Puja Kohli MD MMSc (5,7), Elizabeth W. Karlson MD (4,5,8),  
7 Christopher Newton-Cheh MD MPH (3-6), Hongyu Zhao PhD (2,9), Pradeep Natarajan MD  
8 MMSc (3-6; ORCID: 0000-0001-8402-7435)  
9

- 10 1. Yale School of Medicine, New Haven, CT;  
11 2. Computational Biology & Bioinformatics Program, Yale University, New Haven, CT;  
12 3. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard,  
13 Cambridge, MA;  
14 4. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA;  
15 5. Department of Medicine, Harvard Medical School, Boston, MA;  
16 6. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA;  
17 7. Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston,  
18 MA;  
19 8. Division of Allergy, Immunology, and Rheumatology, Brigham and Women's Hospital,  
20 Boston, MA;  
21 9. Department of Biostatistics, Yale School of Public Health, New Haven, CT  
22

23 Please address correspondence to:

24 Pradeep Natarajan, MD MMSc  
25 [pnatarajan@mgh.harvard.edu](mailto:pnatarajan@mgh.harvard.edu)  
26 185 Cambridge Street, CPZN 3.184, Boston, MA 02114  
27 Tel: 617-724-3526  
28 Fax: 617-726-2203  
29 Twitter: @pnatarajanmd  
30

31 Abstract word count: 258

32 Main text word count: 3,878

33 Main display item count: 4

34 Reference count: 52  
35

36 **Key words:** Pneumonia, Respiratory Infections, Pulmonary Function Tests, Hypertension,  
37 Blood Pressure, Genetic Epidemiology, Population Genetics

1 **Abstract:**

2  
3 **Objectives** – To determine whether elevated blood pressure influences risk for respiratory  
4 infection.

5  
6 **Design** – Prospective, population-based epidemiological and Mendelian randomisation studies.

7  
8 **Setting** – UK Biobank.

9  
10 **Participants** – 377,143 self-identified British descent (54% women; median age 58 years)  
11 participants in the UK Biobank.

12  
13 **Main outcome measures** – First incident pneumonia over an average of 8 follow-up years.

14  
15 **Results** – 107,310 (30%) participants had hypertension at UK Biobank enrolment, and 9,969  
16 (3%) developed a pneumonia during follow-up. Prevalent hypertension at baseline was  
17 significantly associated with increased risk for incident respiratory disease including pneumonia  
18 (hazard ratio 1.36 (95% confidence interval 1.29 to 1.43),  $P < 0.001$ ), acute respiratory distress  
19 syndrome or respiratory failure (1.43 (1.29 to 1.59),  $P < 0.001$ ), and chronic lower respiratory  
20 disease (1.30 (1.25 to 1.36),  $P < 0.001$ ), independent of age, age<sup>2</sup>, sex, smoking status, BMI,  
21 prevalent diabetes mellitus, prevalent coronary artery disease, and principal components of  
22 ancestry. Mendelian randomisation analyses indicated that genetic predisposition to a 5 mmHg  
23 increase in blood pressure was associated with increased risk of incident pneumonia for SBP  
24 (1.08, (1.04 to 1.13),  $P < 0.001$ ) and DBP (1.11 (1.03 to 1.20),  $P = 0.005$ ). Additionally, consistent  
25 with epidemiologic associations, increase in blood pressure genetic risk was significantly  
26 associated with reduced forced expiratory volume in the first second, forced vital capacity, and  
27 the ratio of the two ( $P < 0.001$  for all).

28  
29 **Conclusions** – These results strongly suggest that elevated blood pressure independently  
30 increases risk for pneumonia and reduces pulmonary function. Maintaining adequate blood  
31 pressure control, in addition to other measures, may reduce risk for pneumonia. Whether the  
32 present findings are generalizable to novel coronavirus disease 2019 (COVID-19) require  
33 further study.

1 **Summary Box:**  
2

3 **Section 1: What is already known on this topic**

- 4 • Hypertension has been associated with pneumonia in small observational studies.  
5 • Based on early epidemiologic analyses, hypertension is described as a risk factor for  
6 SARS-CoV-2 infection and associated novel coronavirus disease 2019 (COVID-19).  
7 • The influence of hypertension on pneumonia risk is difficult to assess in traditional  
8 observational studies.  
9

10 **Section 2: What this study adds**  
11

- 12 • Our pre-COVID-19 analyses are consistent with a causal relationship between increased  
13 blood pressure and increased risk for incident respiratory infections, as well as between  
14 increased blood pressure and reduced pulmonary function.  
15 • These results support hypertension as a pneumonia risk factor; efforts to optimize blood  
16 pressure may reduce risk for pneumonia.

## 1 **Introduction**

2

3 Hypertension is a highly prevalent, modifiable risk factor for cardiovascular disease and  
4 mortality<sup>1</sup>. Epidemiologic analyses have correlated hypertension with pneumonia risk in small  
5 studies<sup>2,3</sup>. Whether this represents a direct consequence of hypertension or influence of co-  
6 morbid risk factors such as age, diabetes mellitus, air pollution, or smoking is unclear.

7

8 Hypertension has emerged as one of the most well-recognized risk factors for developing novel  
9 coronavirus disease 2019 (COVID-19) from SARS-CoV-2 infection<sup>4-7</sup>. In particular, patients with  
10 COVID-19 who develop acute respiratory distress syndrome (ARDS) are particularly enriched  
11 for hypertension<sup>7</sup>. Angiotensin converting enzyme (ACE) is an endogenous regulator of blood  
12 pressure that is highly expressed in the lung and has been linked to risk for acute respiratory  
13 distress syndrome (ARDS)<sup>8,9</sup>. ACE2, a homolog and endogenous counter-regulator of ACE, is  
14 expressed in a subset of type II alveolar cells and is an important facilitator of cell entry by  
15 SARS-CoV-2<sup>8-10</sup>. ACE2 has also been implicated in lung injury related to other respiratory  
16 viruses and bacterial pathogens<sup>11-13</sup>. While professional societies have encouraged patients to  
17 remain on ACE inhibitors during the present pandemic, recommendations were largely made in  
18 the absence of robust human data.

19

20 Although epidemiologic analyses support a plausible causal relationship between blood  
21 pressure regulation and respiratory infection risk, confounding from comorbid conditions limit  
22 such inference. Importantly, comorbid factors such as advanced age, diabetes mellitus, and  
23 cardiovascular disease have also been described as independent risk factors for pneumonia  
24 previously as well as for COVID-19. Mendelian randomisation is a statistical approach using  
25 genetic proxies for an exposure as opposed to the exposure itself to mitigate risks for  
26 confounding facilitating more robust causal inference<sup>14</sup>. Blood pressure is a highly heritable trait

1 with several known associated genomic loci that may serve as a robust aggregated genetic  
2 proxy for Mendelian randomization<sup>15</sup>.

3  
4 In the UK Biobank prior to the COVID-19 pandemic, we (1) estimate the epidemiologic  
5 association of hypertension with incident pneumonia risk and indices of pulmonary function, and  
6 (2) apply Mendelian randomisation to test the hypothesis that blood pressure independently  
7 causally influences risks for pneumonia and reduced pulmonary function.

8

## 9 **Methods**

10

### 11 **UK Biobank**

12

13 Individual-level genomic data and longitudinal phenotypic data from the UK Biobank, a large-  
14 scale population-based cohort with genotype and phenotype data in approximately 500,000  
15 volunteer participants recruited from 2006-2010 was used<sup>16</sup>. Baseline assessments were  
16 conducted at 22 assessment centres across the UK using touch screen questionnaire, computer  
17 assisted verbal interview, physical tests, and sample collection including for DNA. Additional  
18 details regarding the study protocol are described online ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)). Of 488,377  
19 individuals genotyped in the UK Biobank, we used data for 377,143 participants with white  
20 British ancestry consenting to genetic analyses, with genotypic-phenotypic sex concordance,  
21 without sex aneuploidy, and one from each pair of 1<sup>st</sup> or 2<sup>nd</sup> degree relatives selected randomly.  
22 Participants provided informed consent as previously described. Secondary use of the data was  
23 approved by the Massachusetts General Hospital institutional review board (protocol  
24 2013P001840) and facilitated through UK Biobank Application 7089.

1 Genome-wide genotyping was previously performed in the UK Biobank using two genotyping  
2 arrays sharing 95% of marker content: Applied Biosystems UK BiLEVE Axiom Array (807,411  
3 markers in 49,950 participants) and Applied Biosystems UK Biobank Axiom Array (825,927  
4 markers in 438,427 participants) both by Affymetrix (Santa Clara, CA)<sup>16</sup>. Variants used in the  
5 present analysis include those also imputed using the Haplotype Reference Consortium  
6 reference panel of up to 39 million single nucleotide polymorphisms (SNPs)<sup>17 18</sup>. Poor quality  
7 variants and genotypes were filtered as previously described<sup>16</sup>.

## 8 **Phenotypes**

### 9 10 Hypertension, covariates, and medication measures

11 Disease definitions for hypertension and clinical disease covariates are as previously  
12 described<sup>19</sup>. In brief, hypertension was defined by self-reported hypertension and billing codes  
13 for essential hypertension, hypertensive disease with and without heart failure, hypertensive  
14 heart and renal diseases, and secondary hypertension. Prevalent coronary artery disease  
15 (CAD), was defined by billing codes for heart attack, angina pectoris, unstable angina,  
16 myocardial infarction, coronary atherosclerosis, coronary artery revascularization, and other  
17 acute, subacute, and chronic forms of ischemic heart disease, or with self-reported angina,  
18 heart attack/myocardial infarction, coronary angioplasty +/- stent, or coronary artery bypass  
19 graft (CABG) surgery. Diabetes mellitus included billing codes for type 1, type 2, and gestational  
20 diabetes mellitus, as well as self-reported diabetes mellitus and insulin use.

21 Blood pressure medications were characterized by medication type into angiotensin converting  
22 enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), or other medication. The list of  
23 ACEi and ARBs considered in UK Biobank participants is provided in **Supplementary Table 1**.

1 Patients taking at least one ACEi were included in the ACEi category, patients taking no ACEi  
2 but at least one ARB were included in the ARB category, and patients who reported that they  
3 were taking a blood pressure medication (via UK Biobank Field IDs 6153 and 6177) but were  
4 not taking an ACEi or ARB were included in the 'other' category.

5

## 6 Respiratory outcomes

7 Clinical disease definitions for our primary outcome (pneumonia) and related respiratory  
8 outcomes are detailed in **Supplementary Table 2**. In summary, these included respiratory  
9 diseases using the first reported occurrences of respiratory system disorders in Category 2410  
10 as categorized by the UK Biobank (<http://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=2410>)  
11 which maps primary care data, ICD-9 and ICD-10 codes from hospital inpatient data, ICD-10  
12 codes in death register records, and self-reported medical conditions reported at the baseline, to  
13 ICD-10 codes. For each set of phenotypes, the time to first incident event after baseline  
14 examination in individuals free of prevalent history of respiratory system disorder was used.  
15 Pneumonia includes viral, bacterial, and unspecified aetiologies (J12-J18). Influenza or viral  
16 pneumonia includes confirmed or suspected influenza or viral pneumonia (J09-J12). The acute  
17 upper respiratory infections category includes acute nasopharyngitis, sinusitis, pharyngitis,  
18 tonsillitis, laryngitis, tracheitis, croup, epiglottitis, or upper respiratory infections of multiple and  
19 unspecified sites (J00-J06). The other acute lower respiratory infections category includes acute  
20 bronchitis, bronchiolitis, or unspecified acute lower respiratory infections (J20-J22). The other  
21 diseases of the upper respiratory tract category includes rhinitis, nasopharyngitis, pharyngitis,  
22 chronic sinusitis, nasal polyps, other disorders of the nose and nasal sinuses, chronic diseases  
23 of the tonsils and adenoids, peritonsillar abscess, chronic laryngitis, laryngotracheitis, diseases  
24 of the vocal cords and larynx, or other diseases of the upper respiratory tract (J30-J39). Chronic  
25 lower respiratory diseases include bronchitis, emphysema, chronic obstructive pulmonary  
26 disease, asthma, bronchiectasis (J40-J47). Other interstitial respiratory diseases refer to acute

1 respiratory distress syndrome (ARDS), pulmonary oedema, or other interstitial pulmonary  
2 diseases (J80, J81, J84). Respiratory failure refers to J96 (respiratory failure not elsewhere  
3 classified).

4  
5 Quantitative phenotypes included best-measure pulmonary function tests from spirometry using  
6 a Vitalograph Pneumotrac 6800 (Buckingham, United Kingdom), including forced expiratory  
7 volume in the first second (FEV1), forced vital capacity (FVC), and the ratio of these two  
8 measurements (FEV1/FVC). For each individual measurement, extreme outliers were  
9 determined and filtered by adjusting the traditional box and whisker upper and lower bounds  
10 and accounting for skewness in the phenotypic data identified using the Robustbase package in  
11 R (setting range=3) (<https://cran.r-project.org/web/packages/robustbase/robustbase.pdf>).

12 Phenotypes were then inverse rank normalized to mean 0 and standard deviation (SD) 1 for  
13 analysis.

## 15 **Statistical methods**

### 17 Association between prevalent hypertension and respiratory conditions in the UK Biobank

18 Phenotypic association of prevalent hypertension with incident respiratory diseases and with  
19 pulmonary function tests was performed using Cox proportional hazards models among  
20 individuals without the corresponding prevalent condition in R (version 3.5, R Foundation,  
21 Vienna, Austria). The proportional hazards assumption was assessed by Schoenfeld residuals  
22 and was satisfied. The sparsely adjusted model included age, age<sup>2</sup>, sex, smoking status  
23 (current, previous, or never smoker), and the first ten principal components of ancestry. The  
24 fully adjusted model additionally incorporated body-mass index (BMI), prevalent diabetes  
25 mellitus, and prevalent coronary artery disease.

26

1 Genetic instruments for blood pressure and association analyses

2 One-sample Mendelian randomisation was performed in the UK Biobank by associating inverse-  
3 rank normalized systolic blood pressure and diastolic blood pressure polygenic risk scores (SBP  
4 PRS, DBP PRS) with incident respiratory disease phenotypes. The 75 variants comprising each  
5 genetic instrument (**Supplementary Tables 3, 4**) were determined by identifying genome-wide  
6 significant ( $P < 5 \times 10^{-8}$ ), largely uncorrelated (linkage disequilibrium  $r^2 < 0.2$ ) variants for each  
7 phenotype from the International Consortium for Blood Pressure (ICBP) GWAS summary  
8 statistics across 299,024 individuals among 77 cohorts excluding the UK Biobank<sup>15</sup>.

9  
10 Additive polygenic risk scores were determined as such:  $\sum_{i=1}^{75} Beta \times SNP_{ij}$ , where *Beta* is the  
11 weight for each allele of  $SNP_i$  from the ICBP GWAS summary statistics, and  $SNP_{ij}$  is the  
12 number of alleles (i.e., 0, 1, or 2) for  $SNP_i$  in participant *j* in the UK Biobank. To confirm that the  
13 SBP PRS and DBP PRS were strong instruments, we assessed their associations with SBP and  
14 DBP, adjusted for blood pressure medications by adding 15 and 10 mmHg to SBP and DBP,  
15 respectively, as previously done<sup>20 21</sup>. Each genetic instrument was validated against its  
16 exposure by calculating an F-statistic derived from unadjusted linear regression of the exposure  
17 against its PRS. An F-statistic greater than 10 indicates low risk of weak-instrument bias.

18  
19 Additional sensitivity analyses tested associations between each PRS and potential social and  
20 lifestyle confounders including the Townsend deprivation index for socioeconomic status  
21 estimation<sup>22</sup>, smoking status (Field ID 20116), alcohol intake frequency (Filed ID 1558),  
22 vegetable serving intake (Field ID 104060), handfuls of sweet intake (Field ID 102330),  
23 significant life stressor over the past two years (Field ID 6145), and exercise frequency (Field ID  
24 3637).

25

1 Association analysis of the SBP and DBP PRS with incident respiratory diseases was  
2 performed using Cox proportional hazards models in R (version 3.5, R Foundation, Vienna,  
3 Austria), adjusting for age, age<sup>2</sup>, sex, smoking status, and the first ten principal components of  
4 ancestry. The proportional hazards assumption was assessed by Schoenfeld residuals and was  
5 satisfied. Association analyses between the SBP and DBP PRS and pulmonary function tests  
6 was performed using a generalized linear model adjusted for the same covariates.

7  
8 Association of the 75 variants for each PRS with both prevalent and incident pneumonia was  
9 performed using a logistic regression Wald test in Hail-0.2, adjusting for age, age<sup>2</sup>, sex, smoking  
10 status, the first ten principal components of ancestry, and genotype array. Using these  
11 associations, two-sample Mendelian randomization was performed using the ICBP-derived SBP  
12 and DBP genetic instruments as exposures and the respective effects of each variant on  
13 pneumonia in the UK Biobank as outcomes. Two-sample Mendelian randomization was  
14 performed using both the robust, penalized inverse variance weighted (IVW) method from the  
15 MendelianRandomization package in R<sup>23 24</sup>, as well as robust adjusted profile score (MR-  
16 RAPS)<sup>25</sup> for comparison. IVW 2-sample Mendelian randomization uses a weighted linear  
17 regression of the ratio of the SNP effects on the outcomes to the SNP effects on the risk factor,  
18 without using an intercept term. MR-RAPS models the systematic pleiotropy using a random  
19 effects model to create a robust adjusted profile score. We additionally use the TwoSampleMR  
20 package in R (<https://mrcieu.github.io/TwoSampleMR/index.html>) to perform multiple sensitivity  
21 analyses including heterogeneity tests, the MR Egger intercept test for horizontal pleiotropy, and  
22 leave-one-out analyses to determine if there is a single variant driving the genetic association.

23

## 24 **Results**

25

### 26 **Baseline characteristics**

1  
2 A total of 377,143 genotyped individuals in the UK Biobank passed quality control criteria.  
3 Among these individuals, median age was 58 [interquartile range 51-63] years, 202,369 (53.7%)  
4 were female, 18,943 (5.0%) had diabetes mellitus, 107,310 (29.7%) had hypertension, and  
5 20,825 (5.7%) had coronary artery disease. 170,713 (45.4%) of individuals were prior or current  
6 smokers, and 85,565 (22.6%) of individuals were on antihypertensive medications  
7 **(Supplementary Table 5).**

8  
9 Across an average follow-up time of 8 years (IQR 7-11 years), 9,969 (2.6%) individuals  
10 developed a pneumonia, 11,972 (3.3%) developed influenza or pneumonia, 18,172 (5.5%)  
11 developed an acute upper respiratory infection, 21,734 (6.2%) developed other lower respiratory  
12 infection (e.g., bronchitis), 12,963 (4.0%) developed a chronic lower respiratory disease, 1,792  
13 (0.5%) developed other interstitial respiratory disease, and 2,621 (0.7%) developed ARDS or  
14 respiratory failure.

15  
16 **Epidemiological association of prevalent hypertension with incident respiratory disease**

17  
18 Prevalent hypertension was independently associated with risk of incident respiratory disease  
19 including pneumonia (1.36 (1.29 to 1.43),  $P < 0.001$ ), chronic lower respiratory disease (1.30,  
20 (1.25 to 1.36),  $P < 0.001$ ), influenza or pneumonia (1.31 (1.25 to 1.37),  $P < 0.001$ ), ARDS or  
21 pulmonary failure (1.43 (1.29 to 1.59),  $P < 0.001$ ), other lower respiratory infections (1.15 (1.37 to  
22 1.45),  $P < 0.001$ ), other acute upper respiratory infection (1.06 (1.11 to 1.19),  $P = 0.002$ ), other  
23 interstitial respiratory disease (1.16 (1.02 to 1.31),  $P = 0.022$ ), and influenza or viral pneumonia  
24 (1.12 (1.01 to 1.23),  $P = 0.032$ ), after adjustment for age, age<sup>2</sup>, sex, smoking status, BMI,  
25 prevalent diabetes, prevalent coronary artery disease, and the first ten principal components of  
26 population stratification (**Figure 1**).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## Epidemiological association of antihypertensive use with incident pneumonia

Among the participants, ACEi were prescribed for 37,865 (10.0%), ARBs for 13,207 (3.5%), and other antihypertensives for 34,493 (9.1%). Prescriptions for ACEi, ARBs, or other antihypertensive medicines were similarly associated with increased risk for incident pneumonia (**Figure 2**). However, upon further adjustment for prevalent hypertension status, we did not observe an association of these medication classes with risk for pneumonia.

## Genetic association of blood pressure with incident respiratory disease

We first used one-sample Mendelian randomisation to determine whether a genetic predisposition to increased blood pressure is associated with increased risk for incident pneumonia as well as other respiratory diseases.

Our SBP and DBP genetic instruments each consisted of 75 independent variants (linkage disequilibrium  $r^2 < 0.2$ ) that were genome-wide significant among 299,024 individuals external to the UK Biobank from the International Consortium for Blood Pressure Genomics. The resulting PRS for SBP and, separately, for DBP were significantly associated with their respective phenotypes in the UK Biobank, with each SD increase in the SBP PRS increasing SBP by 2.26mmHg (F-statistic: 4176) and each SD increase in the DBP PRS increasing DBP by 1.32 mmHg (F-statistic: 4785) (**Supplementary Table 6**). 53 SNPs (or SNPs in perfect linkage disequilibrium) were common to both SBP and DBP PRS. Sensitivity analyses were performed to assess for potential social and lifestyle confounders associating with the SBP and DBP PRS, and found no significant associations between the PRS and the Townsend deprivation index for socioeconomic status estimation, smoking status, alcohol intake frequency, vegetable intake,

1 sweet intake, significant life stressor in the past two years, or exercise frequency

2 **(Supplemental Table 7).**

3  
4 Each SD increase in the SBP PRS was associated with a significant increased risk of incident  
5 pneumonia (1.04 (1.02 to 1.06),  $P < 0.001$ ), influenza or pneumonia (1.03 (1.01 to 1.05),  
6  $P = 0.003$ ), and other lower respiratory infection (1.02 (1.00 to 1.03),  $P = 0.029$ ). Each SD increase  
7 in the DBP PRS was also associated with an increased risk of incident pneumonia (1.03, (1.01  
8 to 1.05),  $P = 0.005$ ), and other lower respiratory infections (1.02 (1.00 to 1.03),  $P = 0.012$ ) **(Figure**  
9 **3)**. Accordingly, each 5mmHg increase in SBP conferred by the SBP PRS was associated with  
10 a significant increased risk of incident pneumonia (1.08 (1.04 to 1.13),  
11  $P < 0.001$ ), influenza or pneumonia (1.06 (1.02 to 1.11),  $P = 0.003$ ), and other lower respiratory  
12 infection (1.03 (1.00 to 1.06),  $P = 0.029$ ). Additionally, each 5mmHg increase in DBP conferred  
13 by the DBP PRS was associated with an increased risk of incident pneumonia (1.11, (1.03 to  
14 1.20),  $P = 0.005$ ), and other lower respiratory infections (1.07 (1.01 to 1.12),  $P = 0.012$ ).

15  
16 Two-sample Mendelian randomization was additionally performed using pneumonia association  
17 statistics, from the UK Biobank, for the 75 variants, with blood pressure summary statistics  
18 external to the UK Biobank as above. Both penalized, robust, inverse-variance weighted (IVW)  
19 and robust adjusted profile score (MR-RAPS)<sup>25</sup> methods produced similarly significant results  
20 **(Supplementary Table 8)**. Sensitivity analyses were additionally performed to analyse the  
21 robustness of the results. Across both SBP and DBP genetic instruments, the IVW  
22 heterogeneity test and the MR Egger regression intercept term are both insignificant, suggesting  
23 negligible contribution of heterogeneity and directional horizontal pleiotropy **(Supplementary**  
24 **Table 8)**. Additionally, the Steiger directionality test<sup>26</sup> suggests the correct causal direction of  
25 blood pressure on pneumonia. Lastly, leave-one-out analyses was additionally performed,  
26 suggesting that no single SNP drives the observed association **(Supplementary Figure 1)**.

1 Variants previously described to influence *ACE* expression in the lung (rs145126552,  
2 rs4277405) or kidney (rs6504163) in GTEx<sup>27</sup>, were not individually associated with pneumonia  
3 risk ( $P>0.05$ ).

#### 5 **Epidemiological association of prevalent hypertension with pulmonary function tests**

6  
7 Secondary analyses identified significant associations between prevalent hypertension and  
8 reduced pulmonary function tests (FEV1: -0.088 SD (-0.09 to -0.08),  $P<0.001$ ; FVC: -0.85 SD (-  
9 0.09 to -0.08),  $P<0.001$ ; FEV1/FVC: -0.013 SD (-0.02 to -0.01),  $P<0.001$ ), independent of age,  
10 age<sup>2</sup>, sex, smoking status, body mass index, prevalent coronary artery disease, prevalent  
11 diabetes mellitus, and the first ten principal components of ancestry (**Figure 4A**).

#### 13 **Genetic association of blood pressure with pulmonary function tests**

14  
15 Each SD increase in SBP PRS was significantly associated with reduced pulmonary function  
16 tests (FEV1: -0.007 SD (-0.01 to -0.005),  $P<0.001$ ; FVC: -0.003 SD (-0.005 to -0.001),  
17  $P=5.91\times 10^{-3}$ ; FEV1/FVC: -0.014 SD, (-0.017 to -0.011),  $P<0.001$ ). Similar associations were  
18 identified for between DBP PRS and pulmonary function tests (FEV1: -0.005 SD(-0.008 to -  
19 0.003),  $P<0.001$ ; FVC: -0.003 SD (-0.005 to 0),  $P=0.02$ ; FEV1/FVC: -0.009 SD, (-0.013 to -  
20 0.006),  $P<0.001$ ) (**Figure 4B**).

#### 22 **Discussion**

23  
24 In a large, prospective, population-based cohort, we show that prevalent hypertension is a risk  
25 factor for incident pneumonia, lower respiratory infections, ARDS or respiratory failure, as well  
26 as many other respiratory diseases. Additionally, our epidemiological analyses also

1 demonstrate an association between prevalent hypertension and increased pulmonary  
2 obstruction as indicated by reduced FEV1/FVC. Our Mendelian randomisation studies imply that  
3 the relationship between increased blood pressure with increased risk for pneumonia as well as  
4 reduced pulmonary function may be causal.

5  
6 Our findings may have important implications for the prevention of pneumonia. First, our study  
7 establishes that hypertension is an important independent risk factor for the development of  
8 pneumonia. Our observation is consistent with prior unadjusted estimates in retrospective  
9 analyses<sup>2,28</sup>. Although significantly associated, the effect of hypertension adjusted for important  
10 confounders on future risk for pneumonia is more moderate, as anticipated. Furthermore, our  
11 genetic analyses are consistent with a causal relationship between blood pressure and  
12 pneumonia. Hypertension has been proposed to promote key factors which may predispose to  
13 infection via several potential mechanisms. (1) Hypertensive stimuli promote dysregulation of  
14 the adaptive immune response. Chronic angiotensin II infusions in mice increase markers of T  
15 lymphocyte activation and perivascular adipose infiltration<sup>29</sup>. Additional murine studies have  
16 indicated that monocytes and neutrophils may be key factors in angiotensin II-mediated  
17 hypertension and resultant vascular dysfunction<sup>30,31</sup>. A recent Mendelian randomisation study  
18 supported a causal relationship between blood pressure and subsequent alteration in  
19 neutrophil, monocyte, and eosinophil indices<sup>32</sup>. (2) Endothelial dysfunction as a consequence of  
20 hypertension may promote infection. Dysregulation of nitric oxide release and signalling in  
21 murine models of pulmonary inflammation leads to exacerbated lung injury<sup>33</sup>. Furthermore,  
22 superoxides generated from endothelial NADPH oxidase may play a role in exacerbating  
23 influenza-associated lung injury in experimental models<sup>34</sup>.

24  
25 Second, in addition immunologic and vascular effects, blood pressure elevations may result in  
26 pulmonary function alterations predisposing to the development of pneumonia. Our Mendelian

1 randomisation analyses with pulmonary function tests support a causal association between  
2 increased blood pressure and indices of increased pulmonary obstruction as indicated by  
3 reduced FEV1/FVC. Several prior studies have linked hypertension with decreased  
4 performance on pulmonary function tests, reduced lung function, and increased pulmonary  
5 obstruction<sup>35-37</sup>. Chronic obstructive pulmonary disease (COPD) is a well-established risk factor  
6 for pneumonia, and is co-morbid with several cardiovascular diseases and risk factors including  
7 hypertension<sup>38</sup>. Our study extends these observations to show that increased blood pressure  
8 may causally lead to increased pulmonary obstruction representing a putative mechanism  
9 toward heightened pneumonia risk. Together, these studies and others suggest several  
10 mechanisms which may link hypertension and pulmonary obstruction: 1) both may involve  
11 physiological degradation of arterial and airway elasticity<sup>37</sup>, 2) endothelial and vascular  
12 dysfunction may also influence pulmonary vascular endothelial cells and lead to pulmonary  
13 vascular dysfunction resulting in lung tissue destruction and airway obstruction<sup>40</sup>, and 3)  
14 systemic inflammation associated with hypertension may additionally alter pulmonary function<sup>41</sup>  
15 <sup>32</sup>.

16  
17 Third, since our results are consistent with a causal relationship between blood pressure and  
18 pneumonia risk, blood pressure optimization is anticipated to reduce pneumonia risk in the  
19 population orthogonal to other strategies aimed at reducing infection risk. Since *ACE* is highly  
20 expressed in the lung with adverse effects, such as cough, there were initial concerns about  
21 ACEi potentially exacerbating pulmonary diseases or leading to pulmonary infections. The  
22 observational association of antihypertensives with increased pneumonia risk is rendered  
23 nonsignificant when adjusting for hypertension consistent with confounding by indication. A  
24 meta-analysis comprising of randomized controlled and observational studies indicated that  
25 ACEi may be protective for pneumonia risk<sup>42</sup>. As detailed earlier, since ACE2 may serve as a  
26 receptor for respiratory viral entry and is an endogenous counter-regulator of ACE, conflicting

1 hypotheses for ACEi and COVID-19 risk have emerged<sup>43-45</sup>. We do not observe that genetic  
2 variants influencing the expression of *ACE* in the lung or kidney significantly increase the risk of  
3 pneumonia. Whether genetic variants at *ACE* have outsized influence on COVID-19 risk  
4 requires further study. However, our results are aligned with current recommendations to  
5 maintain stable, normal blood pressure, including with ACEi as indicated<sup>46 47</sup>. Consistent with  
6 this finding, the Systolic Blood Pressure Intervention Trial (SPRINT) also showed that intensive  
7 blood pressure reduction (to a mean SBP of 121 mmHg) resulted in fewer cases of incident  
8 pneumonia (2.1% versus 2.4%) compared to standard blood pressure reduction (to a mean  
9 SBP of 136 mmHg)<sup>48</sup>. Additionally, a separate multi-center study of 1,128 patients with  
10 hypertension diagnosed with COVID-19 showed that inpatient use of ACEi/ARB was associated  
11 with lower risk of all-cause mortality compared with ACEi/ARB non-users (HR 0.37, P=0.03)<sup>49</sup>.  
12 Thus, withdrawal of ACEi and challenges of blood pressure management while promoting  
13 physical distancing, may not only have untoward cardiovascular consequences but may  
14 inadvertently increase pneumonia risk.

15

## 16 **Strengths and limitations**

17

18 This study has several strengths, including the analysis of a large, genotyped population-based  
19 cohort with high fidelity phenotyping, including with subclinical respiratory phenotypes.  
20 Furthermore, diverse phenotyping facilitates extensive individual-level covariate adjustment in  
21 the models and sensitivity analyses to assess for pleiotropy. Our overall study design, with the  
22 incorporation of Mendelian randomisation, permits more robust causal inference in humans  
23 beyond observational prospective analyses. While our study has several strengths, some  
24 limitations should be considered. First, the present analyses were conducted among individuals  
25 of white British ancestry residing in the UK; whether the present findings generalize to diverse  
26 ethnicities and other geographic regions remains to be tested. Second, our model assumes the

1 association of the genetic instrument to the outcome occurs via the primary exposure and is not  
2 confounded by pleiotropy<sup>50 51</sup>. We have performed a number of sensitivity analyses to assess for  
3 possible confounders, in particular, we observe that our genetic instruments for blood pressure  
4 are not associated with key socioeconomic and lifestyle factors influencing both blood pressure  
5 and pneumonia risk. We further maintain a sparsely adjusted model in our one-sample  
6 Mendelian randomization analyses to reduce the potential for collider bias<sup>52</sup>. Additionally,  
7 secondary 2-sample Mendelian randomization analyses provide consistent results with no  
8 evidence of horizontal pleiotropy, heterogeneity, or individual variants driving the association.  
9 Third, while our results do not yield an association between *ACE* eQTLs and pneumonia risk,  
10 we cannot rule out the possibility of reduced power for this analysis. Fourth, outcomes for the  
11 present analyses occurred prior to the COVID-19 pandemic. The first release of COVID-19  
12 phenotypes from the UK Biobank participants has few COVID-19 events (approximately 0.1%),  
13 which limits power. Furthermore, with testing data only in 0.3% of UK Biobank participants,  
14 analyses are currently limited by ascertainment bias. Whether the current findings translate to  
15 COVID-19 require further verification.

16  
17

## 18 **Conclusions:**

19


20 Our study provides evidence that hypertension directly influences the risk of pneumonia.  
21 Vigilance for blood pressure monitoring and management may reduce risk for pneumonia,  
22 including potentially for the ongoing COVID-19 pandemic.

1 Acknowledgments: The authors would like to acknowledge and thank the participants and staff  
2 of the UK Biobank and of the ICBP consortium cohorts. This work was supported by UK  
3 Biobank application number 7089.

4  
5 Funding: S.M.Z. is supported by the National Institutes of Health's NHLBI under award number  
6 1F30HL149180-01 and the National Institutes of Health's Medical Scientist Training Program at  
7 the Yale School of Medicine. M.C.H. is supported by the National Institutes of Health  
8 (T32HL094301-07). P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts  
9 General Hospital, and grants from the National Heart, Lung, and Blood Institute (R01HL1427,  
10 R01HL148565, and R01HL148050) and Fondation Leducq (TNE-18CVD04).


11 Disclosures: P.N. reports investigator-initiated grants from Amgen, Apple, and Boston Scientific,  
12 and consulting income from Apple and Blackstone Life Sciences. The remaining authors have  
13 nothing to disclose.

1 **Figure 1: Epidemiological association of prevalent hypertension with respiratory**  
 2 **diseases**




9  
10  
11 Association between prevalent hypertension (HTN) and incident respiratory disease is shown in  
 12 a sparsely adjusted and fully adjusted model. The sparsely adjusted model is adjusted by age,  
 13 age<sup>2</sup>, sex, smoking status (current, prior, or never smoker), and the first ten principal  
 14 components of population stratification. The fully adjusted model is additionally adjusted by  
 15 prevalent coronary artery disease, prevalent diabetes, and body mass index.  
 16 HTN = Hypertension, ARDS = Adult respiratory disease syndrome, HR = hazard ratio

1 **Figure 2: Epidemiological association of antihypertensive use with incident pneumonia**



2  
3  
4 Association of antihypertensive use with incident pneumonia, adjusted by age, age2, sex,  
5 smoking status, prevalent coronary artery disease, prevalent diabetes, body mass index, and  
6 the first ten principal components of population stratification, displayed with and without  
7 adjusting for prevalent hypertension, suggests that the effect of antihypertensives on increased  
8 risk of incident pneumonia is driven by hypertensive status.  
9 ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, HR =  
10 hazard ratio


1 **Figure 3: Genetic association of blood pressure with incident respiratory disease**  
 2  
 3  
 4




5  
 6  
 7  
 8  
 9 Association of systolic blood pressure polygenic risk score (SBP PRS) and diastolic blood  
 10 pressure polygenic risk score (DBP PRS) with incident respiratory disease, adjusted for age,  
 11 age<sup>2</sup>, sex, smoking status, and the first ten principal components of population stratification in  
 12 the UK Biobank. Effects are interpreted as hazard ratio (HR) per standard deviation (SD)  
 13 increase of the respective PRS. Of note, each SD increase in the SBP PRS increases SBP by  
 14 2.26mmHg, and each SD increase in the DBP PRS increases DBP by 1.32 mmHg in the UK  
 15 Biobank.  
 16 SBP PRS = systolic blood pressure polygenic risk score, DBP PRS = diastolic blood pressure  
 17 polygenic risk score, HR = hazard ratio, SD = standard deviation  
 18

1 **Figure 4: Epidemiological and genetic association of elevated blood pressure with**  
 2 **pulmonary function tests**

3  
 4 **A.**



5  
 6 **B.**



7  
 8  
 9 **A)** Association of prevalent hypertension with pulmonary function tests (PFT), adjusted for age,  
 10 age<sup>2</sup>, sex, smoking status, prevalent coronary artery disease, prevalent diabetes, body mass  
 11 index, and the first ten principal components of population stratification in the UK Biobank. **B)**  
 12 Association of systolic blood pressure polygenic risk score (SBP PRS) and diastolic blood  
 13 pressure polygenic risk score (DBP PRS) with pulmonary function tests (PFT), adjusted for age,  
 14 age<sup>2</sup>, sex, smoking status, and the first ten principal components of population stratification in  
 15 the UK Biobank. Effects are interpreted as SD change in PFT per SD increase of the respective  
 16 PRS. Of note, each SD increase in the SBP PRS increases SBP by 2.26mmHg, and each SD  
 17 increase in the DBP PRS increases DBP by 1.32 mmHg in the UK Biobank.  
 18 FEV1 = Forced expiratory volume in 1-second, FVC = Forced vital capacity, HTN =  
 19 hypertension, PFT = pulmonary function test

1 **References:**

- 2
- 3 1. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the  
4 global burden of raised blood pressure on current and future generations: the Lancet  
5 Commission on hypertension. *Lancet* 2016;388(10060):2665-712. doi: 10.1016/S0140-  
6 6736(16)31134-5 [published Online First: 2016/09/28]
- 7 2. Shen Y, Chen Y, Huang Z, et al. Associations between untraditional risk factors,  
8 pneumonia/lung cancer, and hospital fatality among hypertensive men in Guangzhou  
9 downtown. *Sci Rep* 2020;10(1):1425. doi: 10.1038/s41598-020-58207-z [published  
10 Online First: 2020/01/31]
- 11 3. Okaishi K, Morimoto S, Fukuo K, et al. Reduction of risk of pneumonia associated with use of  
12 angiotensin I converting enzyme inhibitors in elderly inpatients. *Am J Hypertens*  
13 1999;12(8 Pt 1):778-83. doi: 10.1016/s0895-7061(99)00035-7 [published Online First:  
14 1999/09/10]
- 15 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel  
16 coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497-506. doi: 10.1016/S0140-  
17 6736(20)30183-5 [published Online First: 2020/01/28]
- 18 5. Wang C, Liu L, Hao X, et al. Evolving Epidemiology and Impact of Non-pharmaceutical  
19 Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China. *medRxiv*  
20 2020:2020.03.03.20030593. doi: 10.1101/2020.03.03.20030593
- 21 6. Wang Z, Yang B, Li Q, et al. Clinical Features of 69 Cases with Coronavirus Disease 2019 in  
22 Wuhan, China. *Clin Infect Dis* 2020 doi: 10.1093/cid/ciaa272 [published Online First:  
23 2020/03/17]
- 24 7. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress  
25 Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,  
26 China. *JAMA Intern Med* 2020 doi: 10.1001/jamainternmed.2020.0994 [published Online  
27 First: 2020/03/14]
- 28 8. Wosten-van Asperen RM, Lutter R, Haitsma JJ, et al. ACE mediates ventilator-induced lung  
29 injury in rats via angiotensin II but not bradykinin. *Eur Respir J* 2008;31(2):363-71. doi:  
30 10.1183/09031936.00060207 [published Online First: 2007/10/26]
- 31 9. Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion  
32 polymorphism is associated with susceptibility and outcome in acute respiratory distress  
33 syndrome. *Am J Respir Crit Care Med* 2002;166(5):646-50. doi: 10.1164/rccm.2108086  
34 [published Online First: 2002/09/03]
- 35 10. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in  
36 SARS coronavirus-induced lung injury. *Nat Med* 2005;11(8):875-9. doi:  
37 10.1038/nm1267 [published Online First: 2005/07/12]
- 38 11. Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza  
39 H7N9 virus-induced acute lung injury. *Sci Rep* 2014;4:7027. doi: 10.1038/srep07027  
40 [published Online First: 2014/11/14]
- 41 12. Gu H, Xie Z, Li T, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by  
42 respiratory syncytial virus. *Sci Rep* 2016;6:19840. doi: 10.1038/srep19840 [published  
43 Online First: 2016/01/28]
- 44 13. Sodhi CP, Nguyen J, Yamaguchi Y, et al. A Dynamic Variation of Pulmonary ACE2 Is  
45 Required to Modulate Neutrophilic Inflammation in Response to *Pseudomonas*  
46 *aeruginosa* Lung Infection in Mice. *J Immunol* 2019;203(11):3000-12. doi:  
47 10.4049/jimmunol.1900579 [published Online First: 2019/10/28]

- 1 14. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a  
2 guide, glossary, and checklist for clinicians. *BMJ* 2018;362:k601. doi: 10.1136/bmj.k601  
3 [published Online First: 2018/07/14]
- 4 15. Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million  
5 people identifies 535 new loci associated with blood pressure traits. *Nat Genet*  
6 2018;50(10):1412-25. doi: 10.1038/s41588-018-0205-x [published Online First:  
7 2018/09/19]
- 8 16. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping  
9 and genomic data. *Nature* 2018;562(7726):203-09. doi: 10.1038/s41586-018-0579-z  
10 [published Online First: 2018/10/12]
- 11 17. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for  
12 genotype imputation. *Nat Genet* 2016;48(10):1279-83. doi: 10.1038/ng.3643 [published  
13 Online First: 2016/08/23]
- 14 18. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data on ~500,000 UK  
15 Biobank participants. *bioRxiv* 2017 doi: 10.1101/166298
- 16 19. Zekavat SM, Aragam K, Emdin C, et al. Genetic Association of Finger  
17 Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and  
18 Coronary Artery Disease. *Arterioscler Thromb Vasc Biol* 2019;39(6):1253-61. doi:  
19 10.1161/ATVBAHA.119.312626 [published Online First: 2019/05/10]
- 20 20. Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association analysis identifies  
21 novel blood pressure loci and offers biological insights into cardiovascular risk. *Nat*  
22 *Genet* 2017;49(3):403-15. doi: 10.1038/ng.3768 [published Online First: 2017/01/31]
- 23 21. Tobin MD, Sheehan NA, Scurrah KJ, et al. Adjusting for treatment effects in studies of  
24 quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat Med*  
25 2005;24(19):2911-35. doi: 10.1002/sim.2165 [published Online First: 2005/09/10]
- 26 22. Townsend P, Phillimore P., Beattie A. Health and deprivation. Inequality and the North.  
27 *Health Policy* 1989;10(2)
- 28 23. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing  
29 Mendelian randomization analyses using summarized data. *Int J Epidemiol*  
30 2017;46(6):1734-39. doi: 10.1093/ije/dyx034 [published Online First: 2017/04/12]
- 31 24. Burgess S, Bowden J, Dudbridge F, et al. Robust instrumental variable methods using  
32 multiple candidate instruments with application to Mendelian randomization. *ArXiv e-*  
33 *prints* 2016. <https://ui.adsabs.harvard.edu/#abs/2016arXiv160603729B> (accessed June  
34 01, 2016).
- 35 25. Zhao QW, J.; Hemani, G.; Bowden, J.; Small S.D. Statistical inference in two-sample  
36 summary-data Mendelian randomization using robust adjusted profile score. *ArXiv e-*  
37 *prints* 2018(1801.09652)
- 38 26. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely  
39 measured traits using GWAS summary data. *PLoS Genet* 2017;13(11):e1007081. doi:  
40 10.1371/journal.pgen.1007081 [published Online First: 2017/11/18]
- 41 27. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, et al. Genetic  
42 effects on gene expression across human tissues. *Nature* 2017;550(7675):204-13. doi:  
43 10.1038/nature24277 [published Online First: 2017/10/13]
- 44 28. Shen Y, Tian Z, Lu D, et al. Impact of pneumonia and lung cancer on mortality of women  
45 with hypertension. *Sci Rep* 2016;6(1):20. doi: 10.1038/s41598-016-0023-2 [published  
46 Online First: 2017/04/27]

- 1 29. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II  
2 induced hypertension and vascular dysfunction. *J Exp Med* 2007;204(10):2449-60. doi:  
3 10.1084/jem.20070657 [published Online First: 2007/09/19]
- 4 30. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate  
5 angiotensin II-induced arterial hypertension and vascular dysfunction. *Circulation*  
6 2011;124(12):1370-81. doi: 10.1161/CIRCULATIONAHA.111.034470 [published  
7 Online First: 2011/08/31]
- 8 31. Morton J, Coles B, Wright K, et al. Circulating neutrophils maintain physiological blood  
9 pressure by suppressing bacteria and IFN $\gamma$ -dependent iNOS expression in the  
10 vasculature of healthy mice. *Blood* 2008;111(10):5187-94. doi: 10.1182/blood-2007-10-  
11 117283 [published Online First: 2008/02/19]
- 12 32. Siedlinski M, Jozefczuk E, Xu X, et al. White Blood Cells and Blood Pressure: A Mendelian  
13 Randomization Study. *Circulation* 2020 doi: 10.1161/CIRCULATIONAHA.119.045102  
14 [published Online First: 2020/03/10]
- 15 33. Speyer CL, Neff TA, Warner RL, et al. Regulatory effects of iNOS on acute lung  
16 inflammatory responses in mice. *Am J Pathol* 2003;163(6):2319-28. doi: 10.1016/S0002-  
17 9440(10)63588-2 [published Online First: 2003/11/25]
- 18 34. Selemidis S, Seow HJ, Broughton BR, et al. Nox1 oxidase suppresses influenza a virus-  
19 induced lung inflammation and oxidative stress. *PLoS One* 2013;8(4):e60792. doi:  
20 10.1371/journal.pone.0060792 [published Online First: 2013/04/12]
- 21 35. Jankowich MD, Taveira T, Wu WC. Decreased lung function is associated with increased  
22 arterial stiffness as measured by peripheral pulse pressure: data from NHANES III. *Am J*  
23 *Hypertens* 2010;23(6):614-9. doi: 10.1038/ajh.2010.37 [published Online First:  
24 2010/03/13]
- 25 36. Amaral AF, Patel J, Gnatiuc L, et al. Association of pulse wave velocity with total lung  
26 capacity: A cross-sectional analysis of the BOLD London study. *Respir Med*  
27 2015;109(12):1569-75. doi: 10.1016/j.rmed.2015.10.016 [published Online First:  
28 2015/11/11]
- 29 37. Duprez DA, Hearst MO, Lutsey PL, et al. Associations among lung function, arterial  
30 elasticity, and circulating endothelial and inflammation markers: the multiethnic study of  
31 atherosclerosis. *Hypertension* 2013;61(2):542-8. doi:  
32 10.1161/HYPERTENSIONAHA.111.00272 [published Online First: 2013/01/04]
- 33 38. Mullerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic  
34 literature review. *Chest* 2013;144(4):1163-78. doi: 10.1378/chest.12-2847 [published  
35 Online First: 2013/06/01]
- 36 39. Zhu Z, Wang X, Li X, et al. Genetic overlap of chronic obstructive pulmonary disease and  
37 cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis.  
38 *Respir Res* 2019;20(1):64. doi: 10.1186/s12931-019-1036-8 [published Online First:  
39 2019/04/04]
- 40 40. Iyer KS, Newell JD, Jr., Jin D, et al. Quantitative Dual-Energy Computed Tomography  
41 Supports a Vascular Etiology of Smoking-induced Inflammatory Lung Disease. *Am J*  
42 *Respir Crit Care Med* 2016;193(6):652-61. doi: 10.1164/rccm.201506-1196OC  
43 [published Online First: 2015/11/17]
- 44 41. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.  
45 *J Allergy Clin Immunol* 2016;138(1):16-27. doi: 10.1016/j.jaci.2016.05.011 [published  
46 Online First: 2016/07/05]

- 1 42. Caldeira D, Alarcao J, Vaz-Carneiro A, et al. Risk of pneumonia associated with use of  
2 angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic  
3 review and meta-analysis. *BMJ* 2012;345:e4260. doi: 10.1136/bmj.e4260 [published  
4 Online First: 2012/07/13]
- 5 43. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at  
6 increased risk for COVID-19 infection? *Lancet Respir Med* 2020;8(4):e21. doi:  
7 10.1016/S2213-2600(20)30116-8 [published Online First: 2020/03/15]
- 8 44. Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System  
9 Inhibitors in Patients with Covid-19. *N Engl J Med* 2020 doi: 10.1056/NEJMSr2005760  
10 [published Online First: 2020/04/01]
- 11 45. Danser AHJ, Epstein M, Battlle D. Renin-Angiotensin System Blockers and the COVID-19  
12 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System  
13 Blockers. *Hypertension* 2020:HYPERTENSIONAHA12015082. doi:  
14 10.1161/HYPERTENSIONAHA.120.15082 [published Online First: 2020/03/27]
- 15 46. Boszhurt BKRHB. HFSA/ACC/AHA statement addresses concerns re: using RAAS  
16 antagonists in COVID-19: AHA Science News; 2020 [Available from:  
17 [https://professional.heart.org/professional/ScienceNews/UCM\\_505836\\_HFSAACCAHA](https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA_statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID.jsp)  
18 [statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID.jsp](https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA_statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID.jsp).
- 19 47. G. S. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and  
20 Angiotensin Receptor Blockers: European Society of Cardiology; 2020 [Available from:  
21 [https://www.escardio.org/Councils/Council-on-Hypertension-\(CHT\)/News/position-](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang)  
22 [statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang).
- 23 48. Group SR, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus  
24 Standard Blood-Pressure Control. *N Engl J Med* 2015;373(22):2103-16. doi:  
25 10.1056/NEJMoa1511939 [published Online First: 2015/11/10]
- 26 49. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme  
27 Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With  
28 Hypertension Hospitalized With COVID-19. *Circ Res* 2020 doi:  
29 10.1161/CIRCRESAHA.120.317134 [published Online First: 2020/04/18]
- 30 50. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic  
31 disease: challenges in evaluating causality. *Nat Rev Cardiol* 2017;14(10):577-90. doi:  
32 10.1038/nrcardio.2017.78 [published Online First: 2017/06/02]
- 33 51. Bennett DA, Holmes MV. Mendelian randomisation in cardiovascular research: an  
34 introduction for clinicians. *Heart* 2017;103(18):1400-07. doi: 10.1136/heartjnl-2016-  
35 310605 [published Online First: 2017/06/10]
- 36 52. Paternoster L, Tilling K, Davey Smith G. Genetic epidemiology and Mendelian  
37 randomization for informing disease therapeutics: Conceptual and methodological  
38 challenges. *PLoS Genet* 2017;13(10):e1006944. doi: 10.1371/journal.pgen.1006944  
39 [published Online First: 2017/10/06]

40